|
1
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parikh A, Lee C, Joseph P, Marchini S,
Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, et al:
MicroRNA-181a has a critical role in ovarian cancer progression
through the regulation of the epithelial-mesenchymal transition.
Nat Commun. 5:29772014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsumura N, Huang Z, Mori S, Baba T,
Fujii S, Konishi I, Iversen ES, Berchuck A and Murphy SK:
Epigenetic suppression of the TGF-beta pathway revealed by
transcriptome profiling in ovarian cancer. Genome Res. 21:74–82.
2011. View Article : Google Scholar :
|
|
6
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of Snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikushima H and Miyazono K: TGFbeta
signalling: A complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kavsak P, Rasmussen RK, Causing CG, Bonni
S, Zhu H, Thomsen GH and Wrana JL: Smad7 binds to Smurf2 to form an
E3 ubiquitin ligase that targets the TGF beta receptor for
degradation. Mol Cell. 6:1365–1375. 2000. View Article : Google Scholar
|
|
10
|
Eichhorn PJ, Rodón L, Gonzàlez-Juncà A,
Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A,
et al: USP15 stabilizes TGF-β receptor I and promotes oncogenesis
through the activation of TGF-β signaling in glioblastoma. Nat Med.
18:429–435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee YK, Lee SY, Park JR, Kim RJ, Kim SR,
Roh KJ and Nam JS: Dysadherin expression promotes the motility and
survival of human breast cancer cells by AKT activation. Cancer
Sci. 103:1280–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lubarski I, Asher C and Garty H: FXYD5
(dysadherin) regulates the paracellular permeability in cultured
kidney collecting duct cells. Am J Physiol Renal Physiol.
301:F1270–F1280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lubarski I, Asher C and Garty H:
Modulation of cell polarization by the
Na+-K+-ATPase-associated protein FXYD5
(dysadherin). Am J Physiol Cell Physiol. 306:C1080–C1088. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lubarski-Gotliv I, Dey K, Kuznetsov Y,
Kalchenco V, Asher C and Garty H: FXYD5 (Dysadherin) may mediate
metastatic progression through regulation of the beta-
Na+-K+-ATPase subunit in 4T1 mouse breast
cancer model. Am J Physiol Cell Physiol. 313:C108–C117. 2017.
View Article : Google Scholar
|
|
15
|
Lubarski I, Pihakaski-Maunsbach K, Karlish
SJ, Maunsbach AB and Garty H: Interaction with the Na,K-ATPase and
tissue distribution of FXYD5 (related to ion channel). J Biol Chem.
280:37717–37724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lubarski I, Karlish SJ and Garty H:
Structural and functional interactions between FXYD5 and the
Na+-K+-ATPase. Am J Physiol Renal Physiol.
293:F1818–F1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nam JS, Kang MJ, Suchar AM, Shimamura T,
Kohn EA, Michalowska AM, Jordan VC, Hirohashi S and Wakefield LM:
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of
dysadherin in human breast cancer cells. Cancer Res. 66:7176–7184.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raman P, Purwin T, Pestell R and Tozeren
A: FXYD5 is a marker for poor prognosis and a potential driver for
metastasis in ovarian carcinomas. Cancer Inform. 14:113–119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lubarski Gotliv I: FXYD5:
Na(+)/K(+)-ATPase regulator in health and disease. Front Cell Dev
Biol. 4:262016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCarty KS Jr, Miller LS, Cox EB, Konrath
J and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Jiang HL, Sun HF, Gao SP, Li LD, Huang S,
Hu X, Liu S, Wu J, Shao ZM and Jin W: SSBP1 suppresses TGFβ-driven
epithelial-to-mesenchymal transition and metastasis in
triple-negative breast cancer by regulating mitochondrial
retrograde signaling. Cancer Res. 76:952–964. 2016. View Article : Google Scholar
|
|
25
|
Pathan M, Keerthikumar S, Ang CS, Gangoda
L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim
A, et al: FunRich: An open access standalone functional enrichment
and interaction network analysis tool. Proteomics. 15:2597–2601.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu D, Wolf JK, Scanlon M, Price JE and
Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer
cells correlates with more severe malignancy that can be suppressed
by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
|
|
27
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar
|
|
28
|
Petersen M, Thorikay M, Deckers M, van
Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten
Dijke P and Laping NJ: Oral administration of GW788388, an
inhibitor of TGF-beta type I and II receptor kinases, decreases
renal fibrosis. Kidney Int. 73:705–715. 2008. View Article : Google Scholar
|
|
29
|
Yang H, Wang L, Zhao J, Chen Y, Lei Z, Liu
X, Xia W, Guo L and Zhang HT: TGF-β-activated SMAD3/4 complex
transcriptionally upregulates N-cadherin expression in non-small
cell lung cancer. Lung Cancer. 87:249–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi Y, Wang YF, Jayaraman L, Yang H,
Massagué J and Pavletich NP: Crystal structure of a Smad MH1 domain
bound to DNA: Insights on DNA binding in TGF-beta signaling. Cell.
94:585–594. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang SH, Li J, Al-beit M, Zhang J, Ma D
and Lu X: Screening and identification of potential miRNA involved
in ovarian cancer invasion and metastasis. Zhonghua Zhong Liu Za
Zhi. 32:650–654. 2010.In Chinese. PubMed/NCBI
|
|
32
|
Bai F, Feng J, Cheng Y, Shi J, Yang R and
Cui H: Analysis of gene expression patterns of ovarian cancer cell
lines with different metastatic potentials. Int J Gynecol Cancer.
16:202–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Antonov AV, Krestyaninova M, Knight RA,
Rodchenkov I, Melino G and Barlev NA: PPISURV: A novel
bioinformatics tool for uncovering the hidden role of specific
genes in cancer survival outcome. Oncogene. 33:1621–1628. 2014.
View Article : Google Scholar
|
|
34
|
Ogunjimi AA, Briant DJ, Pece-Barbara N, Le
Roy C, Di Guglielmo GM, Kavsak P, Rasmussen RK, Seet BT, Sicheri F
and Wrana JL: Regulation of Smurf2 ubiquitin ligase activity by
anchoring the E2 to the HECT domain. Mol Cell. 19:297–308. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu
J and Jin W: Loss of RAB1B promotes triple-negative breast cancer
metastasis by activating TGF-β/SMAD signaling. Oncotarget.
6:16352–16365. 2015.PubMed/NCBI
|
|
36
|
Akhurst RJ and Hata A: Targeting the TGFβ
signalling pathway in disease. Nat Rev Drug Discov. 11:790–811.
2012. View Article : Google Scholar : PubMed/NCBI
|
